KNSA FY2025 SEC EDGAR DEF 14A #95 of 168 in industry

Kiniksa Pharmaceuticals International, plc CEO pay ratio

The CEO earned $311K in FY2025 against median worker pay of $310,707 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
X0
Filing date
2026-04-16
Industry
Chemicals & Pharmaceuticals
Industry rank
#95/168

Data updated August 2026

Subscribe to Kiniksa Pharmaceuticals International, plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
35:1
Below Average (Scale: 0–1000:1)
CEO pay
$311K
Median worker
$310,707

Answer first

Kiniksa Pharmaceuticals International, plc's FY2025 CEO total of $311K ranks #1308 of 1,423 complete filings; its 35:1 pay ratio ranks #1109. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $310,707. Industry placement uses the FY2025 SIC-28 peer cohort (# 95 of 168, 44th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1308
$311K of 1,423 FY2025
Ratio rank
#1109
35:1 of 1,423
Industry pct
44th
below the industry median pay ratio

How Kiniksa Pharmaceuticals International, plc ranks nationally

Kiniksa Pharmaceuticals International, plc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$310,707 8th percentile higher than 8% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Kiniksa Pharmaceuticals International, plc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($311K) against pay ratio (35:1) for Kiniksa Pharmaceuticals International, plc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both04601554.09203107.913804661.918406215.933.6:135.8:138:140.2:142.4:1CEO total payPay ratio (CEO : median worker)Kiniksa Pharmaceuticals International, plc, CEO total pay: 310707 · Pay ratio (CEO : median worker): 35:1Kiniksa Pharmaceuticals International, plcEvolus, Inc., CEO total pay: 6412214 · Pay ratio (CEO : median worker): 35:1Evolus, Inc.Geron Corp, CEO total pay: 314826 · Pay ratio (CEO : median worker): 35:1Geron CorpPrecigen, Inc., CEO total pay: 5354329 · Pay ratio (CEO : median worker): 34:1Precigen, Inc.Rhythm Pharmaceuticals, Inc., CEO total pay: 17544525 · Pay ratio (CEO : median worker): 36:1Rhythm Pharmaceuticals, Inc.Cryoport, Inc., CEO total pay: 2392161 · Pay ratio (CEO : median worker): 37:1Cryoport, Inc.
Kiniksa Pharmaceuticals International, plc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Kiniksa Pharmaceuticals International, plc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Kiniksa Pharmaceuticals International, plc

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
35:1
FY2025
vs prior FY
+10:1
from FY2024 25:1
CEO $ YoY
+8.6%
$311K latest
Filings shown
2
FY2024–2025
Kiniksa Pharmaceuticals International, plc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $286K - $286,186 25:1 -
2025 $311K +8.6% $310,707 35:1 +10:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1730430, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
35:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$311K
Companies in Industry
168
vs. Industry Median
Below
#95 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Kiniksa Pharmaceuticals International, plc: MODEST · MICRO pay ratio

Kiniksa Pharmaceuticals International, plc's FY2025 CEO total $311K ranks #1308 of 1,423 complete filings (lower third by dollars). the CEO earned 35× the median employee ($310,707) in FY2025.

Median employee $310,707 (ELITE-MED); MODEST · MICRO stamps put about 35 median-wage years per CEO year.

CEO Total Pay

$311K

FY2025 Summary Compensation, below median

Pay Ratio

35:1

Below typical

Kiniksa Pharmaceuticals International, plc in the lower-dollar third

Kiniksa Pharmaceuticals International, plc's FY2025 CEO total $311K ranks #1308 of 1,423 complete filings (lower third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Kiniksa Pharmaceuticals International, plc's $311K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1308 and ratio rank #1109 split - treat 35:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$311K
Median Employee Pay
$310,707
Pay Ratio
35:1
Filing Date
2026-04-16

Company Info

Ticker
KNSA
CIK
1730430
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
X0
View SEC filings →
SEC EDGAR DEF 14A for CIK 1730430, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Kiniksa Pharmaceuticals International, plc's FY2025 CEO total $311K ranks #1308 of 1,423 complete filings (lower third by dollars).

Read with Kiniksa Pharmaceuticals International, plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MICRO · ELITE-MED.

Grand Canyon Education, Inc. · MICRO

ABS(ceo_total_comp) peer at $311K (Δ $132 lighter vs Kiniksa Pharmaceuticals International, plc); FLOOR · PAR-MED vs this page's MODEST · MICRO · ELITE-MED.
Burford Capital Ltd · MICRO

ABS(ceo_total_comp) peer at $309K (Δ $2K lighter vs Kiniksa Pharmaceuticals International, plc); MODEST · ELITE-MED vs this page's MODEST · MICRO · ELITE-MED.
Park Aerospace Corp · MICRO

ABS(ceo_total_comp) peer at $303K (Δ $7K lighter vs Kiniksa Pharmaceuticals International, plc); FLOOR · PAR-MED vs this page's MODEST · MICRO · ELITE-MED.
Aurinia Pharmaceuticals Inc. · MICRO

ABS(ceo_total_comp) peer at $320K (Δ $10K heavier vs Kiniksa Pharmaceuticals International, plc); FLOOR · ELITE-MED vs this page's MODEST · MICRO · ELITE-MED.
Evolus, Inc. (SIC 28 pole)

Evolus, Inc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Kiniksa Pharmaceuticals International, plc's MODEST filing.
National dual ranks · #1308/#1109

Kiniksa Pharmaceuticals International, plc's FY2025 package sits #1308 by CEO dollars and #1109 by ratio under MICRO · MODEST.
Ratio primer · MODEST

Kiniksa Pharmaceuticals International, plc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Kiniksa Pharmaceuticals International, plc (CIK 1730430), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.